Neurogene Inc. (NGNE)

NGM – Цена в реальном времени. Валюта: USD

37.03

+1.24 (3.45%)

Рынок открыт: Aug 12, 2026, 11:53 AM EDT

35.09

-0.71 (-1.98%)

Предыдущая сессия: Aug 11, 2026, 4:37 PM EDT

11.08.2026

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2026 financial results and highlighted recent corporate updates. “The second quarter and recent months marked important progress across our NGN-401 program, highlighted by positive long-term Phase 1/2 data showing durable, multidomain developmental gains that have not be.

04.08.2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company's common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Induce.

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

04.08.2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 12,555 shares of the Company's common stock to four new employees (the “Inducement Grants”) on August 3, 2026 (the “Grant Date”). The Induce.

Neurogene Inc. (NGNE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neurogene Inc. (NGNE)

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Neurogene Inc. (NGNE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Neurogene Inc. (NGNE)

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Видео

No Data

Пресс-релизы

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)